The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh ... third FDA-approved biosimilar of Actemra and will be available in both intravenous (IV) and subcutaneous ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...

FDA approved another biosimilar to tocilizumab (Actemra), branded as Avtozma, for the intravenous or subcutaneous treatment of rheumatoid arthritis, COVID-19, and other tocilizumab-approved ...

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA ®. AVTOZMA is indicated for the treatment of multiple diseases including rheumatoid arthritis ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra ... offering of both intravenous and subcutaneous formulations of tocilizumab and is targeting the number ...